文献速递帕金森病与运动障碍

血液甲基化组改变作为散发性帕金森病潜在表观遗传生物标志物

Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's Disease.
PubMed 文献 · Ann Neurol · 2024-04-02

基于PPMI队列,比较196例散发性帕金森病患者与86例健康对照的全血DNA甲基化,发现基线时5178个CpG位点差异甲基化,其中579个在3年内显著变化,CYP2E1和NDRG4基因附近位点及CTSH高甲基化伴表达降低具潜在生物标志物价值。

要点

  • 基线时PD患者与健康对照间有5178个CpG位点差异甲基化,其中高甲基化2683个、低甲基化2495个。
  • 579个CpG位点在3年内发生显著甲基化变化,CYP2E1和NDRG4基因附近位点值得关注。
  • CTSH基因高甲基化伴随其表达降低,提示表观遗传调控与基因表达相关。

核心结论

  • 提供初步证据表明PD患者血液DNA甲基化改变可能作为疾病潜在表观遗传生物标志物,需更长间隔及前驱期进一步分析以评估其在整个PD进展中的意义。

研究设计与样本

  • 基于帕金森病进展标志物倡议(PPMI)队列,使用全血对196例散发性PD患者和86例健康对照进行纵向DNA甲基化分析,并对差异甲基化CpG位点对应基因行RNA测序基因表达分析。

主要发现

  • 入组时PD患者 compared to 健康对照有5178个CpG位点差异甲基化(高甲基化2683个,低甲基化2495个)。
  • 其中579个CpG位点在3年内发生显著甲基化变化。
  • 多个差异甲基化CpG位点位于细胞色素P450家族2亚家族E成员1(CYP2E1)基因附近,多个高甲基化CpG位点与N-myc下游调节基因家族成员4(NDRG4)基因相关。
  • RNA测序分析显示PD患者 compared to 对照有75个差异表达基因。
  • 整合分析发现20个基因呈现低甲基化伴随过表达,1个基因组织蛋白酶H(CTSH)显示高甲基化 associated with 其表达降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需在更长间隔及疾病前驱期进行额外分析以评估这些变化在PD进展中的意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize DNA methylation (DNAm) differences between sporadic Parkinson's disease (PD) and healthy control (HC) individuals enrolled in the Parkinson's Progression Markers Initiative (PPMI). METHODS: Using whole blood, we characterized longitudinal differences in DNAm between sporadic PD patients (n = 196) and HCs (n = 86) enrolled in PPMI. RNA sequencing (RNAseq) was used to conduct gene expression analyses for genes mapped to differentially methylated cytosine-guanine sites (CpGs). RESULTS: At the time of patient enrollment, 5,178 CpGs were differentially methylated (2,683 hypermethylated and 2,495 hypomethylated) in PD compared to HC. Of these, 579 CpGs underwent significant methylation changes over 3 years. Several differentially methylated CpGs were found near the cytochrome P450 family 2 subfamily E member 1 (CYP2E1) gene. Additionally, multiple hypermethylated CpGs were associated with the N-myc downregulated gene family member 4 (NDRG4) gene. RNA-Seq analyses showed 75 differentially expressed genes in PD patients compared to controls. An integrative analysis of both differentially methylated sites and differentially expressed genes revealed 20 genes that exhibited hypomethylation concomitant with overexpression. Additionally, 1 gene, cathepsin H (CTSH), displayed hypermethylation that was associated with its decreased expression. INTERPRETATION: We provide initial evidence of alterations in DNAm in blood of PD patients that may serve as potential epigenetic biomarker of disease. To evaluate the significance of these changes throughout the progression of PD, additional profiling at longer intervals and during the prodromal stages of disease will be necessary. ANN NEUROL 2024;95:1162-1172.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Latapi P, Bustos B, Dong S, et al. Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's Disease. Ann Neurol. 2024. PMID: 38563317. doi:10.1002/ana.26923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。